BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Senetek PLC (SNTK) Reports Third Quarter 2009 Financial Results


11/17/2009 10:58:50 AM

NAPA, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Senetek PLC , a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced revenues for its fiscal third quarter ended September 30, 2009 were $550,000, compared with $424,000 in the quarter ended June 30, 2009 and $483,000 reported in the comparable prior year period ended September 30, 2008.

Gross profit margin for the third quarter of 2009 showed an increase to 63% versus third quarter 2008 at 58% of revenue. Skincare gross profit rate for the three months ended September 30, 2009, increased to 93% from 77% for the three months ended September, 2008, due to sales of higher margin Pyratine-6 and PyratineXR products in the current quarter. Pharmaceutical gross profit was consistent at 55% for the three months ended September 30, 2009 and 2008.

Senetek PLC recently announced the hiring of Miller Tabak + Co., LLC as financial and strategic advisors. The Board has retained the firm to evaluate the Company's technology and business model and to make recommendations on the development of a plan that will benefit shareholders. Once the Board approves a definitive plan of action or a transaction, a public announcement will be made and a shareholder teleconference will be scheduled.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

CONTACT: Mike Rosen, mrosen@bratskeir.com, or Tara Madden,
tmadden@bratskeir.com, both of Bratskeir & Company, +1-212-679-2233, for
Senetek PLC; or William O'Kelly of Senetek PLC, +1-707-226-3900, ext. 102

Web site: http://www.Senetekplc.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->